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Abstract
Background and Aim: Intraperitoneal transplantation of alginate-
microencapsulated human hepatocytes is an attractive option for the management
of acute liver failure (ALF) providing short-term support to allow native liver
regeneration. The main aim of this study was to establish an optimised protocol for
production of alginate-encapsulated human hepatocytes and evaluate their
suitability for clinical use.
Methods: Human hepatocyte microbeads (HMBs) were prepared using sterile
GMP grade materials. We determined physical stability, cell viability, and
hepatocyte metabolic function of HMBs using different polymerisation times and
cell densities. The immune activation of peripheral blood mononuclear cells
(PBMCs) after co-culture with HMBs was studied. Rats with ALF induced by
galactosamine were transplanted intraperitoneally with rat hepatocyte microbeads
(RMBs) produced using a similar optimised protocol. Survival rate and biochemical
profiles were determined. Retrieved microbeads were evaluated for morphology
and functionality.
Results: The optimised HMBs were of uniform size (583.5¡3.3 mm) and
mechanically stable using 15 min polymerisation time compared to 10 min and
20 min (p,0.001). 3D confocal microscopy images demonstrated that hepatocytes
with similar cell viability were evenly distributed within HMBs. Cell density of
3.56106 cells/ml provided the highest viability. HMBs incubated in human ascitic
fluid showed better cell viability and function than controls. There was no significant
activation of PBMCs co-cultured with empty or hepatocyte microbeads, compared
to PBMCs alone. Intraperitoneal transplantation of RMBs was safe and significantly
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improved the severity of liver damage compared to control groups (empty
microbeads and medium alone; p,0.01). Retrieved RMBs were intact and free of
immune cell adherence and contained viable hepatocytes with preserved function.
Conclusion: An optimised protocol to produce GMP grade alginate-encapsulated
human hepatocytes has been established. Transplantation of microbeads provided
effective metabolic function in ALF. These high quality HMBs should be suitable for
use in clinical transplantation.
Introduction
Acute liver failure (ALF) is a devastating condition which causes an abrupt loss of
hepatic function leading to encephalopathy, coagulopathy and progressive
multiple organ failure. The mortality of ALF is high without orthotopic liver
transplantation [1]. Liver transplantation is an effective treatment but suffers from
following limitations scarcity of organ donors, surgical risk, and requirement for
life-long immunosuppression. Intrahepatic hepatocyte transplantation has shown
benefit as a bridge to transplantation [2, 3]. However, invasive catheter placement
in the liver in a coagulopathic patient and use of immunosuppression are
perceived as high risk factors. Hence a technique that would avoid use of
immunosuppression and transplantation of cells in a body cavity that easily
accessible will be an ideal scenario. Alginate encapsulated microencapsulated
hepatocytes seems to be the best fit [4, 5]. The principle of the microencapsulation
technique is that the cells are embedded in a semi-permeable polymerised
structure with the aim of protecting cells from host immune attack, while
permitting the diffusion of nutrients, oxygen and metabolic products which
maintain cell survival and function [6]. Thus this approach allows cell
transplantation without using immunosuppression and also avoids the risk of
bleeding. Microencapsulation could also protect hepatocytes from cryoinjury
leading to improved cell viability and function [7, 8], allowing cryopreserved cells
to be available for emergency transplantation in ALF patients.
Microbeads need to maintain their integrity during transplantation and within
the implant site, as damage would result in functional loss of cells and immune
rejection [9]. The mechanical stability can be optimised by factors such as time of
cross-linking (polymerisation), and spatial distribution of cells. However,
increasing the strength of microbeads could reduce permeability which may
undermine cell viability and function, therefore, these properties need to be
optimised [10].
The biomaterial of the microbeads, or antigens/chemokines released through
the pores of the microbeads from encapsulated cells, may initiate a host immune
response and subsequently lead to an inflammatory reaction and cell death [11].
The degree of alginate purity has been shown to be of great importance in both in
vitro and in vivo studies [12]. Our main aim was to produce high quality
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microencapsulated hepatocytes using materials of good manufacturing practice
(GMP) grade for clinical use.
In this study we optimised the microbeads by studying the effects of
polymerisation time and cell density on physical integrity and hepatocyte-specific
functions in vitro. We investigated transplantation of rat hepatocyte microbeads in
vivo to evaluate the efficacy and safety of transplantation in a rat model of ALF
using D-galactosamine (D-GalN) administration.
Materials and Methods
Ethics statements
All human tissues were approved for research use in accordance with the Research
Ethics Committee of King’s College Hospital. Written informed consent was
obtained from donor relatives or patients.
All animal experiments were performed following protocols approved by the
Ethical Review Process of King’s College London in accordance with the UK
Animals (Scientific) Procedures Act of 1986.
Hepatocyte isolation
Human hepatocyte isolation
Human hepatocytes were isolated from donor liver tissues (rejected or unused for
transplantation) or from the non-tumoral margin of liver resections from
metastatic cancer cases using a collagenase perfusion technique according to Mitry
(2009) [13]. Total hepatocyte number and their viability were estimated using the
standard trypan blue exclusion test; cell viability was >60%. In some experiments
cryopreserved human hepatocytes were used [14].
Rat hepatocyte isolation
Rat hepatocyte isolation was performed using in situ collagenase perfusion of the
liver as previously published [15, 16]. Isolated hepatocytes were purified by three
times low speed centrifugation (50xg, 4 C˚ for 5 min) and washed with ice-cold
EMEM. The total number of hepatocytes and viability were determined using the
standard trypan blue exclusion test.
Microencapsulation of hepatocytes (hepatocyte microbeads)
Human hepatocyte microbeads
Empty and human hepatocyte microbeads (EMBs and HMBs) were produced
using the IE-50R encapsulator (Inotech Encapsulation AG, Dottikon,
Switzerland), and sterile clinical grade and GMP materials. Ultra-pure sodium
alginate, with low viscosity and high glucoronic acid (PRONOVA SLG20;
NovaMatrix, Sandvika, Norway) was dissolved in 0.9% NaCl to give a final
concentration of 1.5% alginate solution (w/v). HMBs were produced using a
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250 mm nozzle, and polymerised in 1.2% CaCl2 solution. The microbeads were
washed twice with 0.9% NaCl to remove excess Ca2+ ions.
Rat hepatocyte microbeads
Rat hepatocyte microbeads (RMBs) were prepared using the optimised protocol
that has been established in this study. Preliminary studies had shown that this
protocol was also optimal for rat hepatocytes. After production, microbeads were
allocated for in vitro study and transplantation. RMBs were maintained in CMRL
prior to transplantation.
Hepatocyte microbeads culture
HMBs or RMBs were re-suspended in culture medium consisting of CMRL
(Mediatech, Inc., Vancouver, Canada) supplemented with 10% heat-inactivated
FCS, 2 mM L-glutamine, 0.1 mM dexamethasone, 0.1 mM insulin (Sigma-Aldrich,
Gilingham, UK), and penicillin (50 U/ml) and streptomycin (50 mg/ml, Gibco,
Paisley, UK). Microbeads were maintained in this culture medium at a ratio of 1:4
(microbeads: medium; v:v) in a humidified incubator at 37 C˚ and 5% CO2 for 3
days. Supernatants were changed every alternate day and were collected at each
time point according to the experimental setting (day 1, 2, 3 and 7) for analysis.
Cell membrane integrity assay and overall metabolic activity
assays
Microbeads (100 ml) were washed with Dulbecco’s phosphate-buffered saline
(DPBS; Gibco), then resuspended in 1 ml DPBS containing 10 mg fluorescein
diacetate (FDA; Sigma-Aldrich) and 20 mg propidium iodide (PI; Sigma-Aldrich),
and incubated in the dark for 90 sec at room temperature (RT). Microbeads were
washed three times with DPBS followed by adding VECTASHIELD Mounting
Media (Vector Laboratories Ltd., Peterborough, UK) then visualised under a
fluorescent microscope (Leica Microsystems Ltd, Milton Keynes, UK). Live cell
cytoplasm appeared bright green (FDA), while dead cells had bright red-stained
nuclei (PI). The overall metabolic activity of encapsulated hepatocytes was
evaluated by measuring the reduction of tetrazolium salt [3-(4, 5-dimethylthiazol-
2-yl)-2,-5 diphenyltetrazolium bromide; MTT], [17]. The values were expressed as
mean OD reading¡SEM per 100 mg microbeads.
Hepatocyte-specific functions
The amount of albumin secreted by HMBs and RMBs over 24 h was quantified
using the Human and Rat Albumin sandwich enzyme-linked-immunosorbent-
assay (ELISA) Quantitation Kit (Bethyl Laboratories, Tx, USA), respectively. Urea
synthesis was assessed after challenging hepatocytes with ammonium chloride
(5 mM) for 6 h at 37 C˚. Supernatant was collected and analysed using the
QuantiChrom Urea Assay Kit (BioAssay Systems, CA, USA). Cytochrome P450
(CYP1A1/2) activity was measured using the ethoxyresorufin O-deethylase
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(EROD) method [18]. Fluorescence was measured at 530 nm excitation/590 nm
emission using a Tecan Genios Pro plate reader (Tecan Group Ltd., Ma¨nnedrof,
Switzerland). Total amount of resorufin produced was calculated using a
resorufin standard curve (0–800 pmol).
Assessment of physical integrity of microbeads-osmotic pressure
test
HMBs were produced using 3 different polymerisation times (10, 15, and
20 min). Physical stability of microbeads was determined using an osmotic stress
test. To establish the stability of microbeads preliminary experiments were done
on EMBs. Based on these results, the integrity of HMBs was determined in CMRL
(isotonic solution) and water (hypotonic solution). HMBs were assessed after 3 h
of exposure to osmotic shock by measuring the diameter of 100 microbeads per
sample under a light microscope, and using Image J software (ver. 1.44p, National
Institutes of Health, USA). Microbeads immediately after production were used as
controls.
Effect of polymerisation time on hepatocyte viability and function
in HMBs
To study the effect of polymerisation time in CaCl2 on hepatocyte viability and
function, three polymerisation times (10, 15, and 20 min) were used in the
production of HMBs. Samples of HMBs were exposed to the osmotic stress test
followed by MTT assay to assess overall cell viability. Other HMBs samples were
maintained in culture supplemented in CMRL medium for 24 h, followed by
assessment of cell viability and hepatocyte-specific functions.
Effects of cell density on microbead morphology, cell viability and
function
HMBs were produced using 4 cell densities: 2.0, 2.5, 3.0 and 3.5 million cells/ml
alginate using the same batch of cryopreserved human hepatocytes for each
experiment. Cell density of 4.06106 cells/ml alginate was also studied in
preliminary experiments, however, it was observed that the HMBs obtained varied
in size (range: 400-1200 mm), and some had a distorted shape. Microbead
morphology was examined immediately after production (control). HMBs were
maintained in culture in complete CMRL for 3 days, and cell viability was assessed
at day1.
Confocal microscopy was used to reconstruct 3D images of the microbeads.
Briefly, 250 ml HMBs were stained with FDA/PI in DPBS. VECTASHIELD
Mounting Media was added to prevent photo bleaching. HMBs were loaded onto
glass slide with a well followed by addition of a drop of glycerol to minimise
microbeads movement during imaging. The images were captured using a Leica
SP5 confocal microscope (Leica Microsystems Ltd, Milton Keynes, UK). Images
were imported into Volocity software (Perkin Elmer, Cambridge, UK) and then
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into Mathematica 8.0 (Wolfram Inc.,Oxfordsire, UK). This technique determined
cell viability in relation to cell distribution in the microbeads (outer and inner
halves), and the average number of cells per microbead. Hepatocyte-specific
functions were also evaluated on day 1 and day 3.
Effects of ascitic fluid on HMBs
Ascitic fluid was obtained from the abdominal drains of paediatric patients with
ALF. HMBs were incubated in 100%, 50%, 25% ascitic fluid diluted with culture
medium, and full culture medium (control). Cell viability and urea synthesis of
encapsulated hepatocytes were assessed at days 1, 2, 3 and 7. It was difficult to
measure albumin as the level in the ascitic fluid was already high.
Microbeads immunogenicity
Peripheral blood mononuclear cells (PBMCs) were isolated from blood of four
normal healthy donors. The isolated PBMCs were either cultured alone (controls)
or co-cultured with EMBs or HMBs (3.56106 cells/ml alginate) in WEM with
supplements. The cultures were maintained in a humidified incubator at 37 C˚ for
24 h. The ratio of PBMCs to hepatocytes in co-cultures was 1:5, based on
preliminary experiments of direct co-culture of PBMCs and plated hepatocytes.
Microbeads before and after co-culture with PBMCs were examined under a light
microscope to evaluate the extent of cell adhesion to their surface in accordance to
Tam et al (2011), [19]. Measurements of activated PBMCs following co-culture
with either EMBs or HMBs were performed using three-color flow cytometry
(FACS) analysis [20] in the presence of monoclonal antibodies to CD3, CD4,
CD8, CD25, CD14, CD40L, CD38, CD56, CD19, and CD54 according to the
combinations in Table 1.
In vivo experiments
Animals
Sprague Dawley (Harlan Olec, Bicester, UK), male rats 8–10 weeks old and weight
between 200 to 300 g were used as the donor to isolate hepatocytes and recipients
of hepatocyte microbeads. Animals were maintained in conventional housing
facilities and received standard care. They were housed in room kept temperature
at 21¡2 C˚, humidity of 55¡10% and 12-hour light-dark cycle with ad libitum
food and water. The experiments were conducted after acclimatization for 7 days.
Induction of acute liver failure
Acute liver failure was induced with D-GalN. Briefly, D-GalN was freshly prepared
at the time of use by dissolving in dH2O to a final concentration of 240 mg/ml
and adjusted to physiological pH (7.4) using 5 M NaOH. Each rat received a
single intraperitoneal injection of D-GalN at the dose of 1.2 g/kg. After injection,
all animals were allowed a standard diet and 5% dextrose water ad libitum to
prevent hypoglycemia.
Alginate Microencapsulated Hepatocytes
PLOS ONE | DOI:10.1371/journal.pone.0113609 December 1, 2014 6 / 23
Intraperitoneal transplantation of rat hepatocyte microbeads and experimental
groups
Microbeads were transplanted into the peritoneal cavity of ALF animals at 24–
28 h after D-GalN injection. The microbeads were suspended in transplant
medium (CMRL) and were transplanted intraperitoneally via an 18-guage
intravascular catheter into the rats using sterile technique. Each animal received
microbeads suspension at a dose of 10 ml/kg, corresponding to approximately
8.756106 to 10.56106 cells per rat. Animals were anesthetised with isoflurane for
the procedure. The animals were allocated to three experimental groups: group 1
(sham) received vehicle injection of medium only (n55); group 2 transplanted
with EMBs (n54); and group 3 transplanted with fresh RMBs (n55). All animals
received the same volume of fluid.
Measurement of liver function tests and creatinine
Assessment the severity of hepatic damage after D-GalN-induce ALF was
performed on blood samples collected on day 1, 2, 4 and 8 post-ALF induction
compared to day 0 (baseline control). Prothrombin time (PT), ammonia, alanine
aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin and
creatinine were analysed at the same time point. PT and ammonia were
determined using fresh whole blood without anticoagulants (8 ml and 20 ml,
respectively). PT was measured using an automated coagulation monitoring
device (CoaguCheck XS System, Roche Diagnostic, Mannheim, Germany) with a
maximum recorded value of .96 seconds. Ammonia was determined using a
blood ammonia analyser (PocketChem BA, Manarini Diagnostics, Wokingham,
UK). The measurement range of this test is 7–286 mmol/L. ALT, AST, bilirubin
and creatinine were measured in serum samples (150 ml) using a routine
Table 1. Percentage of frequency of activation markers expressed on PBMCs.
Activation marker PBMCs alone PBMCs after co-culture with EMBs PBMCs after co-culture with HMBs
CD3+ CD25+ 9.70¡2.07 10.30¡2.55 9.19¡1.70
CD4+ CD25+ 3.74¡0.69 4.32¡0.94 4.83¡1.07
CD8+ CD25+ 2.36¡0.62 1.85¡0.51 1.65¡0.32
CD14+ CD25+ 45.65¡10.98 22.76¡7.96 2.66¡0.80*
CD14 +CD40L+ 6.39¡1.34 5.32¡1.95 6.36¡2.32
CD3+ CD54+ 14.28¡2.98 13.38¡1.04 11.36¡2.11
CD4+ CD54+ 2.53¡0.73 4.17¡1.17 1.90¡0.69
CD3+ CD56+ 12.75¡3.17 12.10¡1.32 9.40¡1.48
CD8+ CD54+ 13.54¡3.52 12.26¡1.31 12.64¡2.04
CD3+ CD38+ 6.11¡1.14 6.78¡0.68 6.75¡0.89
CD4+ CD38+ 2.72¡0.16 3.22¡0.55 2.12¡0.34
CD8+ CD38+ 10.03¡4.99 11.77¡5.63 9.90¡4.23
CD19+ CD25+ 0.61¡0.24 1.07¡0.29 2.55¡1.04
CD19+ CD54+ 1.10¡0.28 2.30¡0.50 5.54¡2.14
Significance compared to control *p,0.001.
doi:10.1371/journal.pone.0113609.t001
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biochemical AutoAnalyser (Advia 2400; Siemen Healthcare Diagnostics,
Camberley, UK).
Animal follow-up and rat hepatocyte microbeads retrieval
Survival rate was followed for 7 days post transplantation. Animals were
euthanised at day 7 or if any sign of distress was observed. The signs of distress
were marked respiratory depression with cyanosis, rapid weight loss .30% over
24 h, significant bleeding, and marked neurological signs as a consequence of liver
failure which are typically agitation followed by a lack of response to external
stimuli and animals becoming immobile. Microbeads and liver tissue were
harvested from the abdomen by laparotomy. To retrieve microbeads, the
peritoneal cavity was flushed several times with 50 ml CMRL followed by
thorough inspection of the abdominal cavity for signs of inflammation or
adhesion.
Evaluation of retrieved rat hepatocyte microbeads and liver histology
Retrieved microbeads were examined for morphology, including host cell
adhesion to their surface to determine the extent of host immune responses. Cell
viability and function of retrieved microbeads were evaluated after maintenance in
culture for 24 h after retrieval. Histopathology analysis was performed on liver
tissue samples.
Statistical analysis
Data were analysed using GraphPad Prism 6 software (GraphPad, CA, USA). All
data are presented as the mean¡standard error of the mean (mean¡SEM) from
at least 4 independent experiments unless otherwise stated. Student t-test was
applied to compare two independent groups. A two-way measurement ANOVA
and Turkey’s multiple comparisons test were used to compare groups exposed to
different conditions. Survival curves were calculated using the Kaplan-Meier
methods and compared with log-rank test. A p-value of #0.05 was considered
statistically significant.
Results
Effects of polymerisation time on physical integrity and stability of
HMBs
HMBs in all three control groups were uniform with a mean diameter of
584¡0.9 mm (10 min), 582.2¡1.2 mm (15 min), and 584.4¡1.2 mm (20 min),
with no statistical differences between the three polymerisation groups. There was
a significant increase in mean microbeads ’diameter in all samples incubated in
hypotonic solution compared to both control and CMRL groups (p,0.001). The
15 min polymerisation HMBs group had a significantly better mechanical stability
compared to the other two groups (p,0.001) with a mean microbead diameter
Alginate Microencapsulated Hepatocytes
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difference of 7.1 mm (10 min vs 15 min), and 23.5 mm (20 min vs 15 min) after
exposure to water.
Effects of polymerisation time on hepatocyte viability and function
in HMBs
There was no statistically significant difference in cell viability (MTT) between the
three polymerisation times for HMBs under the same conditions. MTT activity
was maintained after 3 h incubation in CMRL compared to control, however, in
all groups there was a marked decrease in cell activity when incubated in water
(p,0.02). HMBs from the three polymerisation groups provided similar
metabolic function after being maintained in culture for 24 h. The amount of
albumin production for 10, 15 and 20 mins group were 569.0¡112.2,
606.3¡97.0, and 581.2¡103.3 ng/mg protein and urea production were 6.1¡1.1,
6.1¡1.2, and 6.4¡1.2 mg/mg protein, respectively.
Effects of cell density on microbead morphology, human
hepatocyte viability and functions
The viability of human hepatocytes before encapsulation was 61.5¡1.1%. HMBs
produced using different cell densities (2.06106 to 3.56 106 cells/ml alginate)
showed uniformity and a smooth outer surface with no significant differences
between all groups. After encapsulation, HMBs were maintained in culture
overnight to allow the encapsulated hepatocytes to stabilise. Cell viability (FDA/PI
staining) showed that the density of 3.56106 cells/ml provided the highest
viability. The 3D reconstructed images showed that cells were evenly distributed
inside the microbead (Figure 1). The average cell number per microbead for each
cell density ranged from 201 (2.06106 cells/ml alginate) up to 447
(3.56106 cells/ml alginate). Surprisingly, as the cell density was increased there
was no significant difference in cell viability between outer and inner halves in all
groups (Figure 2A). The overall viability in the 3.56106 cells/ml group was
significantly higher than 2.06106 cells/ml (46.1¡3.3% vs 31.7¡3.3%, p50.01)
and also tended to be higher than 2.56106 cells/ml (37.42¡5.17%) but did not
reach significance (p50.06). Furthermore, MTT assay on day 1 showed a similar
trend where the 3.56106 cells/ml group had a higher activity than other groups.
However, on day 3 there was a significant decrease in overall activity for 3.06106
and 3.56106 cells/ml (p,0.05; Figure 2B).
Urea and albumin assays showed no significant differences between the 4
groups on either day 1 or day 3 (Figures 2C and D). However, albumin synthesis
showed a similar pattern to cell viability, where the higher cell number gave higher
production. By contrast, the CYP1A1/2 activity on day 3 of the 2.06106 cells/ml
group was significantly higher than 3.0 and 3.56106 cells/ml (p,0.05;
Figure 2E).
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Cell viability and function in HMBs after maintenance in ascitic
fluid
Microbeads cultured in ascitic fluid showed higher cell viability (FDA/PI staining)
than those in supplemented culture medium (controls) at all-time points
(Figure 3A). Similarly, overall cell activity (MTT) of HMBs cultured in ascitic
fluid was significantly higher than controls (p,0.001) on day 1 (OD reading/
100 mg HMBs: 1.49¡0.07 vs. 0.86¡0.04) up to day 7 (0.67¡0.03 vs. 0.18¡0.02)
of culture (Figure 3B). Moreover, urea production showed higher levels in HMBs
incubated in ascitic fluid compared to controls (p,0.001) at all times except on
day 3, and on day 7 urea level was significantly higher (6.3¡0.2 vs 3.6¡0.4 mg/
mg protein, p,0.001), (Figure 3C).
Figure 1. Distribution of human hepatocytes in alginate-hepatocyte microbeads. Representative image
of HMBs produced with different cell densities; 2.0, 2.5, 3.0 and 3.56106 cells/ml alginate (A, B, C, and D
respectively) under light microscopy (left) and fluorescence microscopy (right). Representative confocal
microscopy images used in 3D reconstruction to demonstrate (E & F) cell distribution and viability across the
microbead, and (G) viability of cells within outer half vs inner half of same microbead. Green; viable and red;
dead cells.
doi:10.1371/journal.pone.0113609.g001
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Activation level of PBMCs co-cultured with EMBs and HMBs
After co-culturing microbeads with PBMCs for 24 h, both EMBs and HMBs were
still intact and maintained their uniform shape without any apparent PBMCs
adherent to their surface. The percentage of frequency of activation marker
expression on PBMCs is shown in Table 1. There were no significant differences
in the levels of overall cell activation markers expression (CD3+CD38+,
CD4+CD38+, CD8+CD38+) on PBMCs co-cultured with EMBs or HMBs
compared to PBMCs in monoculture (control). Also, the percentage of
CD4+CD25+, CD3+CD25+, CD8+CD25+ T cells expression did not differ between
the PBMCs co-cultured with microbeads (EMBs or HMBs) and control. The
frequency of CD3+C56+ NK cells; CD19+CD25+and CD19+CD54+ B cells were also
comparable between the three groups. The frequency of CD14+CD25+ activated
monocytes in PBMCs co-cultured with HMBs was significantly lower compared
to those co-cultured with EMBs, and PBMCs monocultures (2.66¡0.8% vs
22.8¡7.7% and 45.7¡11.0%, respectively; p,0.0001).
In Vitro studies of RMBs
The viability of rat hepatocytes used for encapsulation was .70%. After
microencapsulation using the optimised technique, the RMBs obtained were of
uniform shape with viability in the MTT assay of 7.65¡1.26 OD reading/100 mg
microbeads. Over the period of 1 week in culture, although cell viability of RMBs
progressively decreased, hepatocyte-specific functions including albumin pro-
duction and CYP1A1/2 activity was remained stable. Urea production was
decreased on day 3 but then maintained until day 7 (Figure 4).
In Vivo studies
D-GalN at 1.2 g/kg induced ALF defined by PT.36 sec (INR>3) at 24 h after
ALF induction in about 50% of rats. Liver function of ALF-rats was blood
ammonia; median 21 (range 7-58) mmol/l, PT; 66.5 (37.4–96.0) sec, AST; 2260
(1017–6255) IU/l, ALT; 1218 (803–5584) IU/l, and bilirubin; 3 (2–10) mmol/l.
After intraperitoneal transplantation, all animals in the three groups
immediately recovered from the injection without any post-operative complica-
tions or mortality and became ambulatory. Subsequently, two animals in group 2,
transplanted with EMBs, died on day 2 and day 3 post-ALF induction. In group 1,
one animal died on day 3. All animals in group 3 transplanted with RMBs
survived for 1 week post transplantation. The 72-hour survival rates were 80%,
50%, and 100% in group 1, 2 and 3, respectively, after this time the survival rate
did not change in all experimental groups The rats in group 3 (treated with
Figure 2. Effect of cell density on cell viability and human hepatocyte function. Cell viability demonstrated by (A) 3D reconstruction technique and (B)
MTT activity. Hepatocyte functions measured by (C) albumin production, (D) urea production and (E) CYP1A1/2 activity; *p,0.05, **p#0.01, ***p#0.001.
doi:10.1371/journal.pone.0113609.g002
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RMBs) had better survival than the other two groups (untreated and treated with
EMBs); but this was no statistically significant.
The blood chemistry results started to increase from baseline levels significantly
by 24 h and then progressively rose to reach a peak at 48 h after ALF induction
indicating the point of maximal liver injury. A general improvement in liver
function was observed in surviving animals on day 4 post-ALF induction.
Subsequently, all parameters returned to normal levels (baseline) on day 8 post-
ALF induction (Figure 5). There was no significant difference in biochemical
profiles at 24 h after ALF induction with a similar degree of liver injury in all
groups before receiving microbead treatment. The differences between groups
were clearly seen on the following day after transplantation of microbeads. In the
rats in group 3, transplantation with RMBs reduced the severity of ALF with a
statistically significant lower level of ALT, AST and bilirubin than those of group 1
(p,0.0001, p,0.0001 and p,0.001, respectively) and group 2 (p,0.0001,
p,0.0001, and p ,0.01, respectively). In addition, the creatinine level in rats
transplanted with RMBs (24.5, range 22–31 umol/l) was significantly lower than
in those transplanted with EMBs group (48, range 45–51 umol/l; p,0.01). PT and
ammonia levels were not significantly different between the 3 groups.
Microbeads were recovered from surviving animals 7 days after transplantation or
whenever the animals died (or were euthanised). Microbeads were found dispersed
throughout the peritoneal cavity mainly loosely attached to omentum and
mesentery, which came off easily after flushing with transplant medium. No signs of
inflammation or adhesion were observed (Figure 6A). The total volume of capsules
retrieved was found to be 70¡2.4% of those transplanted. The retrieved microbeads
maintained their integrity (Figure 6B). There was hardly any host cell adherent on
the surface of retrieved microbeads (#1%). The retrieved RMBs in group 3 showed
viable cells as demonstrated by FDA/PI staining (Figure 6C) and MTT activity
(0.7¡0.1 OD reading/100 mg RMBs). Hepatocyte function for albumin synthesis
(1033.3¡22.4 ng/mg protein), urea synthesis (10¡5.5 mg/mg protein) and
CYP1A1/2 activity (9.9¡0.1 pmol/mg protein/min) in culture was also seen.
Liver histopathology of surviving rats showed completely normal intact lobular
architecture without signs of hepatocellular injury 1 week post transplantation.
ALF rats that died showed evidence of severe hepatocellular necrosis affecting
periportal and centrilobular region (Figure 7).
Discussion
The ‘‘ideal’’ microbeads must have physical stability and biocompatibility without
compromising the microenvironment inside the microbead to allow long-term
Figure 3. Effect of ascitic fluid on human hepatocyte microbeads (HMBs) cell viability and activity. (A)
FDA/PI staining of HMBs maintained in supplemented culture medium or ascitic fluid at different
concentrations (25%, 50%, and 100%), (B) MTT assay and (C) urea production compared between HMBs
incubated in supplemented culture medium and ascitic fluid, respectively; *P,0.05, **P#0.01, ***P#0.001.
doi:10.1371/journal.pone.0113609.g003
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cell survival and function. After exposure to osmotic stress, HMBs demonstrated
that a polymerisation time of 15 min resulted in more physically stable
microbeads compared to the other two groups. The likely reason for this is that
10 min polymerisation is too short for effective cross-linking and equilibration of
external Ca2+ between the core of alginate and the external medium [21], whereas
an increase in polymerisation time to 20 min made microbeads become brittle
[22, 23]. Our results showed that a prolonged polymerisation time did not have a
negative effect on encapsulated cell viability and function, supporting previous
studies [22, 24].
Figure 4. Cell viability and metabolic functions of optimised rat hepatocyte microbeads (RMBs). (A) Cell viability showed by MTTassay, (B) albumin
production, (C) urea production and (D) CYP1A1/2 activity.
doi:10.1371/journal.pone.0113609.g004
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We investigated the influence of cell density on physical integrity, cell viability
and function in order to establish the optimal ratio of cell mass per microbead to
allow oxygen, nutrients, and metabolite diffusion. The results showed that
microbeads produced using these cell densities 2.06106, 2.56106, 3.06106, and
3.56106 cells/ml, all had a stable physical integrity with a smooth surface, but
when the cell density was increased to 4.06106 cells/ml alginate, surface
irregularities and microbead deformities were observed. These findings are
different from a recently published study by Durkurt and colleagues (2013) who
suggested that for rat hepatocytes the optimal density is 1.06106 cells/ml alginate
[25]. An increase in microbead cell content results in a considerable change in the
microenvironment inside the microbeads with the possibility of apoptotic and
hypoxic cell death particularly towards the microbead centre. It is difficult to
assess the cells while they are entrapped in the three-dimensional structure.
Therefore, we determined the cell number, distribution, and viability across
microbeads using both fluorescent (2D) and confocal (3D) microscopy. It has
been reported that encapsulated hepatocytes lose approximately 20–30% viability
after encapsulation [26]. In this study, cell viability in HMBs was assessed after
maintenance in culture for 1 day instead of immediately after preparation to allow
stabilisation of cells to the microenvironment. We found that 3.56106 cells/ml
alginate HMBs provided the highest cell viability with an overall viability loss after
encapsulation of 24%. It must be noted that, the cell viability loss could be
attributed to quality of the available hepatocytes used, due to steatosis and
cryopreservation injury. In order to improve hepatocyte function and viability,
high quality fresh cells should be used. We are also investigating other methods to
improve the viability of hepatocytes such as co-encapsulation with mesenchymal
stem/stromal cells [27]. Another possibility could be to improve the hepatocyte
function by using short-activating RNA oligonucleotides to enhance liver-specific
gene expression [28]. The 3D confocal microscopy data showed that cell viability
in the centre of the microbead did not decrease as the cell number per microbead
was increased. The gel network of Ca-alginate is an inhomogeneous structure in
which the alginate and calcium concentrations are lower in the core than the outer
part of the microbead [23], thus allowing oxygen, nutrients, and metabolites to
penetrate the microbead. Albumin and urea production tended to be better in the
higher cell density groups but this did not reach statistical significance. CYP1A1/2
activity was, however, lower in the high cell density than the low cell density
groups. Optimisation of the polymerisation time and cell density has contributed
to the improvement in efficiency of the HMBs.
Figure 5. Effect of intraperitoneal transplantation of rat hepatocyte microbeads on biochemical indexes of liver injury. Liver injury was evaluated by
(A) prothrombin time (PT), (B) blood ammonia level, (C) serum aspartate aminotransferase (AST) level, (D) serum alanine aminotransferase (ALT) level, (E)
serum bilirubin level and renal impairment assessed by (F) serum creatinine. Data are expressed as median and range; statistical significance*p,0.05,
**p,0.01, ***p,0.001 and ****p,0.0001.
doi:10.1371/journal.pone.0113609.g005
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We also evaluated this optimised technique for encapsulation of rat
hepatocytes. The RMBs produced showed similar properties to the HMBs with
good morphology and well maintained functionality.
We tested the microbeads in ascitic fluid which mimics the microenvironment
around the HMBs following intraperitoneal transplantation. The data obtained
showed that HMBs maintained their in vitro viability and functions in ascitic fluid
better than in normal culture medium. This could be explained by the
microenvironment characteristics of peritoneal fluid which contains a variety of
soluble factors such as growth factors, cytokines, steroids, angiogenic factors and
trace elements [29, 30].
Animal studies have shown that host immune and inflammatory reactions
towards microbeads (allogenic and xenogenic cells) after intraperitoneal
transplantation could lead to host cell adhesion to the microbead surface.
Figure 6. Intraperitoneal transplantation of rat hepatocyte microbeads in rats with ALF. Representative
images of (A) microbeads 7 days post-transplantation distributed throughout abdominal cavity [black arrow]
without any signs of inflammation or adhesion; and (B) recovered microbeads, EMBs (left) partly covered by
host cells [black arrow] and RMBs (right) with no evidence of cell adhesion; and (C) viable cells in RMBs
demonstrated by FDA/PI staining.
doi:10.1371/journal.pone.0113609.g006
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Hepatocyte microbeads survived and functioned for up to two weeks, but some
cells died in the centre of the microbead [4, 31]. To our knowledge none of the
published studies have investigated alloimmune reaction against human
hepatocyte microbeads. Therefore, we tested the immunogenicity of GMP grade
HMBs. Our findings demonstrated that both EMBs and HMBs did not elicit
immune activation in vitro. This is probably due to ultrapure sodium alginate
being used and is consistent with other studies testing inflammation and immune
reaction related to the purity of alginate [12, 32]. Rokstad et al (2011) showed that
alginate microbeads are complement compatible [33].
We have also performed preliminary experiments to assess the suitability and
function of optimised HMBs in normal rats. Human albumin was detected in the
serum of rats for the 7 days of study. Explanted microbeads were intact and were
minimally covered with adherent host cells, the hepatocytes were viable, and able
to synthesise albumin and urea in culture (unpublished data). We transplanted
RMBs in rats with ALF so that fresh cells could be used due to the limited and
timely availability of fresh human hepatocytes. This also avoided any possible
xenogeneic reactions using human hepatocytes in rats and may better simulate the
transplantation of HMBs in patients. Our study showed a positive outcome for
intraperitoneal transplantation of optimised microbeads in ALF-rats. The
Figure 7. Livers of rats with ALF. Representative image of gross appearance of liver; (A) surviving rats at
day 7 post transplantation showed normal appearance as normal control rats, and (B) Rats that died at day 2
after D-GalN injection appeared yellowish pale colour, and atrophy. Representative histopathology sections of
liver tissue from rats with D-GalN induced ALF; H&E staining (200x), scale bars5100 mm. (C) surviving rat at
7 days post transplantation showed normal lobular architecture, and (D) rat that died at 48 h after ALF
induction showed confluent hepatocellular necrosis affecting centrilobular region; portal tract [black arrow] and
central lobular region [white arrow].
doi:10.1371/journal.pone.0113609.g007
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technique was safe without any immediate or late complications. The hepatocytes
inside the microbeads survived and were able to function well without using
immunosuppression. Rats with transplantation of RMBs all survived, which
tended to be better than with EMBs and untreated animals, however, it did not
reach statistical significance due to the small numbers. Also the lower mortality of
ALF with D-GalN at this dose [34] made it difficult to assess. However, there was
a significant improvement in biochemical parameters including ALT, AST, and
bilirubin of RMBs groups compared to the other two groups. We also evaluated
serum creatinine to determine the severity of ALF and multiorgan failure and
found that the RMBs group had significantly lower creatinine than EMB group.
The liver histology of surviving rats showed complete recovery after 7 days of
transplantation. Our data suggests that intraperitoneal transplantation of
hepatocytes microbeads containing only a small part of the total liver mass could
support the failing liver and improve the clinical outcome. Umehara et al showed
that transplanting encapsulated cells at 4% of total liver volume improved
metabolism and survival rate of ALF rats [4], whereas others transplanted up to
30% of liver mass [31, 35, 36]. However, the optimal cell number required to
provide efficient function in the clinical setting of ALF remains controversial and
further studies are needed.
Transplantation of the optimised RMBs in vivo also showed encouraging results
in terms of the physical integrity and biocompatibility of hepatocyte microbeads
and their survival and function. The retrieved microbeads were intact and
maintained their shape and size after 1 week in the peritoneal cavity. Most of
microbeads were free from any host cell adhesion. Previous studies reported
transplanted microcapsules (sodium alginate-poly-L-lysine-sodium alginate
copolymer) surrounded by fibrous tissue within 4 days to 2 weeks [4, 37]. In
addition, in our study there was no evidence of fibrosis or tissue adhesion
surrounding the microbeads. This could be due to the clinical grade alginate we
used, which does not provoke the host immune response in keeping with our in
vitro data. The viability and the detection of albumin and urea production, and
cytochrome activity produced by the retrieved RMBs support on-going microbead
function after transplantation.
Currently, a pilot study of treatment of children with acute liver failure by
intraperitoneal transplantation of HMBs is being performed at our centre.
Encapsulation of fresh hepatocytes followed by cryopreservation to establish a
good quality HMBs bank is important for the future. A study to develop protocols
for cryopreservation of hepatocyte microbeads is underway. This will lead to
microbeads being readily available for immediate use in patients with ALF.
In conclusion, an optimised protocol for production of GMP grade human
hepatocyte microbeads has been established. The alginate encapsulated cells
maintained their hepatocyte-specific function in vitro and in vivo. Intraperitoneal
transplantation of optimised RMBs provided metabolic support in ALF without
immunosuppression and without complications. These high quality alginate
human hepatocyte microbeads should be suitable for use in clinical transplanta-
tion.
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